Interleukin-10 (IL-10) is a recently described pteiotropic cytokine secreted mainly by type 2 helper T cells. Previous studies have shown that IL-t0 suppresses cytokine expression by natural killer (NK) and type 1 T cells, thus down-regulating cell-mediated immunity and stimulating humoral responses. We here report that injected IL-t0 protein is an efficient inhibitor of tumor metastasis in experimental (B16-F10) and spontaneous (M27 and Lox human melanoma) metastasis models in vivo at doses that do not have toxic effects on normal or cancer cells. Histological characterization after IL-10 treatment confirmed the absence of CD8 + and CD4 + T cells and macrophages at the sites of tumor growth, but abundant NK cells were localized at these sites. This unexpected finding was confirmed by showing that IL-10 inhibits most B16-F10 and Lox metastases in mice deficient in T or B cells (SCID and nu/nu mice), but not in those deficient in NK cells (beige mice or NK cell--depleted mice). However, IL-t0 downregulation of pro-inflammatory cytokine production and/or recruitment of additional eff~ctor cells may also be involved in the anti-tumor effect at higher local concentrations of IL-t0, since transfected B16 tumor cells expressing high amounts of lL-10 were rejected by normal, nu/nu, or SCID mice at the primary tumor stage, and there was still a 33% inhibition of tumor metastasis in beige mice.
Summary
Interleukin-10 (IL-10) is a recently described pteiotropic cytokine secreted mainly by type 2 helper T cells. Previous studies have shown that IL-t0 suppresses cytokine expression by natural killer (NK) and type 1 T cells, thus down-regulating cell-mediated immunity and stimulating humoral responses. We here report that injected IL-t0 protein is an efficient inhibitor of tumor metastasis in experimental (B16-F10) and spontaneous (M27 and Lox human melanoma) metastasis models in vivo at doses that do not have toxic effects on normal or cancer cells. Histological characterization after IL-10 treatment confirmed the absence of CD8 + and CD4 + T cells and macrophages at the sites of tumor growth, but abundant NK cells were localized at these sites. This unexpected finding was confirmed by showing that IL-10 inhibits most B16-F10 and Lox metastases in mice deficient in T or B cells (SCID and nu/nu mice), but not in those deficient in NK cells (beige mice or NK cell--depleted mice). However, IL-t0 downregulation of pro-inflammatory cytokine production and/or recruitment of additional eff~ctor cells may also be involved in the anti-tumor effect at higher local concentrations of IL-t0, since transfected B16 tumor cells expressing high amounts of lL-10 were rejected by normal, nu/nu, or SCID mice at the primary tumor stage, and there was still a 33% inhibition of tumor metastasis in beige mice.
A number of cytokines have been used with variable success in attempts to control tumor growth and metastasis (1) (2) (3) (4) (5) (6) (7) (8) . Many of these cytokines, such as IL-2, IFN~/, TNFo~, and GM-CSF, also have direct toxic or stimulatory effects on the tumor cells, and may in some cases lead to malignancy of otherwise normal cells (4, 9) , thus complicating their clinical usefulness. We have therefore screened a number ofcytokines for their ability to inhibit tumor metastases, and found that one of them, IL-10, is an efficient inhibitor of tumor metastasis in vivo at doses that do not have a direct effect on normal or cancer cells. IL-10 acts on different cell types, stimulating differentiation of B cells into antibody-secreting cells, and inhibiting the capacity of monocytes/macrophages to present antigens (10) (11) (12) . In addition, IL-10 exerts an indirect effect on the immune system, by inhibiting the secretion of proinflammatory cytokines (IL-1, IL-6, IL-8, GM-CSF, and TNFc~) from type 1 helper T cells, monocytes/macrophages, and polymorphonuclear Ieukocytes, and by inhibiting the secretion of IFN~/by NK cells (12) (13) (14) (15) . Recent studies have shown that IL-IO downregulates cell-mediated responses and favors the humoral arm of immunity by decreasing production of cytokines involved in cell-mediated responses (12) , and that IL-10 increases the susceptibility to bacterial and parasitic infections (16, 17) . We therefore also investigated the mechanism by which IL-10 inhibits tumor metastasis. We find that NK cells are the main effector cells recruited at the nontoxic concentrations of IL-10 used here, although other effector cells and/or mechanisms may also be involved at higher IL-10 concentrations.
Materials and Methods
Tumor Cells and Experimental Animals. For all the experiments described here, 6--8-wk-old female C57/BL6 and BALB/C mice were purchased from Charles River Labs. (Wilmington, MA). The B16-F10 murine melanoma was provided by Dr. I. Fidler and M27 murine lung carcinoma by Dr. P. Brodt. Human IL-10 (hlL-10) was obtained from Schering-Plough Corp. (Union, NJ), and its specific activity was 3.1 • 107 U/rag. Athymic nu/ nu mice, beige mice, and SCID mice were from Harlen Spraque Dawley.
Tumor Measurements. Experimental lung metastases were obtained after intravenous injection of B16-F10 murine melanoma cells in C57/BL6 (H-2 b) mice, athymic nu/nu mice, and beige mice. Spontaneous lung metastases were obtained by subcutaneous injection of M27 Lewis lung carcinoma cells in C57/BL6 mice, and Lox human melanoma cells in SCID mice. hlL-10 (up to 150 ~g/kg) was injected intraperitoneaUy. Tumor diameters were measured with calipers, groups of 10 mice were used for each condition, and each experiment was repeated at least twice. The number of lung metastases was determined in double-blind measurements. Statistical analysis was performed using the nonparametric one tailed Mann-Whitney U test.
For experiments with mice depleted of NK ceils, mice were injected intravenously with 100 I~g of a mAb against NKI.1 (PharMingen, San Diego, CA) on day -1, day 0 and day 1 after injection of tumor cells (1 • 105 ceils/animal). Animals received IgG2a isotype antibodies as a control for the specificity of the anti-NKl.1 mAb. Treatment with hlL-10 started on day 0, day 1 and day 2 after tumor cell injection. Lung metastases were counted on day 14.
For experiments with tumor ceils transfected with the IL-10 gene, cells were co-transfected with pSV2 neo and a plasmid containing the human IL-10 gene. G418-resistant colonies were isolated, and IL-10 protein secretion was measured by ELISA.
Immunohistological Analysis. Sections for immunohistochemistry were prepared and labeled with antibodies as previously described (18) . Monoclonal antibodies against CD3 (500 A2), CD4 (L3T4), CD8 (Lyt2), CD90 (Thy-1), NK-I. 
Results

Direct Effect of lL-IO on Tumor Cells In Vitro and In Vivo.
In preliminary experiments, it was established that hlL-10 does not have direct toxic or stimulatory effects on the tumor cells when tumor cell lines are treated in vitro with up to 1 btg/ml (corresponding to 10 s U/m/) of hlL-10 (not shown). Likewise, no discernible toxic effect was observed in mice when hlL-10 doses as high as 700 txg/kg were used, although primary tumor growth in animals was partially affected by treatment with higher concentrations of hlL-10. Thus, murine monocytic (nu/nu or BALB/c mice) and OVCAR 5 human ovarian (nu/nu mice) primary tumors were not affected by hlL-10 doses from 5 to 250 l*g/kg daily, while higher doses inhibited slightly the growth of B16-F10 murine melanoma (nu/nu or C57/ BL6) and U937 (nu/nu) tumors (<~40% inhibition) (not shown).
Effect of lL-I0 on Tumor Metastasis. In order to measure the effects of IL-10 on tumor metastasis in animals, hlL-10 (up to 150 I~g/kg) was injected intraperitoneally following various doses and schedules. Daily injection of hlL-10 reduced significantly the number of lung metastases in both spontaneous and experimental models. The inhibition was dose-dependent, as shown in Fig. 1 Figure 1 . Inhibitory effect of hlL-10 on lung metastasis in C57/BL6 mice of (A) B16 and (B) M27 tumors. Mice were injected intravenously with 1 • 10 s B16 or subcutaneously with 2 • l0 s M27 cells on day 0, and hlL-10 treatment was initiated on day 1. Mice treated with hlL-10 exhibited a 64.3% (P = 0.008) inhibition of metastasis at a dose of 10 p.g/kg IL-10, 58.8% (P = 0.01) at a dose of 100 I~g/kg, and 68.4% (P = 0.002) at a dose of I50 txg/kg for B16 tumors on day 9 after injection; and mice treated with 100 b~g/kg and 150 ~g/kg ofhlL-10 exhibited a 90.2% (P = 0.003) and 80.4% (P = 0.048) inhibition of metastasis, respectively, for M27 tumors on day 28, compared with the vehicle control groups (Veh).
M27 tumors. Moreover, treatment does not need to begin at the same time as tumor implantation, since administration ofhlL-10 for 3 d starting on the day after tumor cell inoculation results in a 66.1% inhibition of metastases of B 16 tumors (not shown).
It has recently been shown that Chinese hamster ovary (19) or mammary adenocarcinoma cells transfected (20) with the IL-10 gene were less effective at establishing primary tumors than untransfected cells. We therefore injected animals with B16-F10 tumor cells transfected with the gene coding for hlL-10 and secreting different amounts of hlL-10 to ascertain whether they displayed metastatic behavior. Some of the transfected tumor cells were not able to form solid tumors, and metastases were also effectively (2, 3, 21) , helper T cells (22, 23) , cytotoxic T ceils (1, 7, 8) , and NK cells (7, 24) may contribute to the rejection of tumors treated with different cytokines or transfected with genes coding for those cytokines. In order to determine the nature of the effector cells responsible for IL-10-mediated inhibition of tumor metastases, the phenotype of immune cells invading the tissues was studied by immunostaining. Cells expressing markers of helper (CD4+), cytotoxic T (CD8 +) lymphocytes, or macrophages (Mac-1 +, Mac-2 +, Mac-3 +, and the macrophage epitope BMA BM8) were rarely if ever observed (not shown). Few cells expressing NK cell markers were found in normal tissues (not shown) or tumors of untreated mice (Fig. 3 A) , but abundant NK cells were localized in B16 subcutaneous tumors of mice treated with hlL-10 ( Fig. 3 B) and in subcutaneous tumors of mice injected with IL-10 gene--transfected B16 ceils (Fig. 3 C) . When double immunostaining was performed on the cells expressing the NK cell asialo-GMl antigen (Fig. 3 D) , these were found to also express the LGL-1 marker typical of activated large granular lymphocytes (Fig. 3 E) .
Identification of Effector Cells Involved in Metastasis Inhibilion. Previous studies have demonstrated that macrophages
Metastasis Inhibition in Various Mouse Models.
The involvement of NK cells was confirmed by comparing inhibition of tumor metastases in normal C57/BL6 mice, athymic ma/nu mice, SCID mice, beige mice, and mice that had been depleted of NK cells (Table 1) . While hlL-10 inhibited most metastases in nu/nu and SCID mice (65.6 and 64.3% inhibition, respectively), there was little inhibition in beige mice or NK cell-depleted mice (14 and 19%, respectively). These effects were paralleled in experiments with IL-10 gene-transfected cells. There was complete metastasis inhibition in nu/nu and SCID mice when transfected B16-F10 cells were inoculated into the animals, whereas there was only 33% inhibition when the transfected cells were introduced into beige mice. Thus, with both treatments, inhibition was much lower in NK celldeficient mice (beige mice and NK cell-depleted mice) than in SCID or nu/nu mice. inhibited. Fig. 2 A shows the growth in C57/BL6 mice of B16 tumor cells transfected with the hlL-10 gene. No detectable tumor growth was observed with a clone secreting 400-500 ng IL-10/48 h/1 million transfected cells, while significant growth inhibition was also measured for clones expressing lower IL-10 levels (1.4 to 11.8 ng/million cells/ 48 h). Similarly, hlL-10 secretion by these transfected cells inhibited metastasis of all the B16 clones, with inhibition ranging from 85.8 to 100% (Fig. 2 B) . Inhibition of metastasis was also observed with two hlL-10 gene-transfected M27 clones, #G1 (secreting 50 ng/million cells/48 h) and #G3 (28 ng/million cells/48 h), for which inhibition on
Discussion
We used a number of murine and human tumor cell lines to study the effects of recombinant human IL-10 (hiLl0) protein and of tumor cells transfected with the IL-10 gene on tumor metastasis. Experimental lung metastases were obtained after intravenous injection ofB16-F10 murine melanoma cells in normal mice, athymic nu/nu mace, beige mice, and mice depleted of NK cells by antibody treatment; and spontaneous lung metastases were obtained by subcutaneous injection of M27 Lewis lung carcinoma cells in C57/BL6 mice, and Lox human melanoma cells in SCID mice. We found that soluble IL-10 is able to inhibit metastasis of both experimental and spontaneous lung models at IL-10 concentrations that do not have direct in- (29) , and preincubation with IL-10 before exposure to tumor-associated antigens significantly inhibits delayed-type hypersensitivity responses (30) . In contrast, 1L-10 in combination with IL-2 increases IL-2-induced N K cell proliferation, and IL-10 alone induces NK cytotoxicity against NK-resistant tumor cells in vitro (31) . Furthermore, consistent with our results on the inhibition of tumor metastasis in vivo, IL-10 has been reported to render mouse lymphoma cells resistant to CTL and sensitive to NK-mediated tysis in vitro (32) .
Nonetheless, the observation that both 100 btg/kg hlL-10 and cells transfected with the hlL-10 gene caused measurable inhibition in beige mice (14 and 33%, respectively) suggests that, although NK cells may be the predominant effector mechanism responsible for inhibition, IL-10 may also partially inhibit metastases through other means, such as through its ability to downregulate the production of pro-inflammatory cytokines and chemokines (12) , which enhance the expression of tumor cell adhesion molecules and tumor cell migration (33, 34) . In addition, it has recently been reported that transfected adenocarcinoma cells secreting high quantities of IL-10 (1,500--2,000 ng/million cells/48 h) are rejected by a combination of CD8 + T lymphocytes, NK cells and neutrophils (20) , which would also be consistent with our observation that our high IL-10 producing B16-F10 clone (secreting 400-500 ng/million cells/48 h) is rejected at the primary tumor stage in normal, nu/nu and SCID mice, and that there is still 33% inhibition of tumor metastasis in beige mice.
The IL-10-mediated activation/recruitment of NK cells observed in tumor metastases is in distinct contrast to the inhibition of NK cytokine production by monocytes/macrophages (15) . While the mechanism used to activate and/ or recruit NK cells to sites of metastasis in vivo remains to be elucidated, it has recently been reported that IL-10 inhibits the synthesis of transforming growth factor (TGF)-[~ (35) , which is known to suppress activation of NK cells (36, 37) , and that NK cells express the IL-10 receptor (31) . Given the many pleiotropic activities of IL-10, many of which may indirectly affect NK cell function, it will be interesting to identify the multiple pathways by which IL-10 may inhibit tumor metastasis.
The IL-10 protein appears to have its greatest effect on tumor metastasis, although we can not rule out at the moment the possibility that the marginal effects on primary tumor growth may be due to an inability of IL-10 injected intravenously to reach the tumor core, since one of our tumor cell clones transfected with the IL-10 gene (clone #1A) failed to establish primary tumors. Work in our laboratories is in progress to determine if a synergism, acting on both primary and metastasizing tumors, may exist between IL-10 and other cytokines, such as IL-2 and IL-4, which have previously been reported to inhibit primary tumor growth (1, 2, 7, 21) . Cancer treatment with IL-10 to inhibit metastases, combined with other cytokines or surgical intervention to remove primary tumors, may thus provide an effective means of thwarting the spread of many tumors.
